Geographic Atrophy - Pipeline Review, H2 2018 by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
The "Geographic Atrophy - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Geographic Atrophy Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Geographic Atrophy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Geographic Atrophy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Geographic Atrophy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- Achillion Pharmaceuticals Inc
- Acucela Inc
- Alkeus Pharmaceuticals Inc
- Allergan Plc
- Apellis Pharmaceuticals Inc
- Cell Cure Neurosciences Ltd
- Colby Pharmaceutical Co
- F. Hoffmann-La Roche Ltd
- Foamix Pharmaceuticals Ltd
- Genentech Inc
- GenSight Biologics SA
- Ionis Pharmaceuticals Inc
- Johnson & Johnson
- Novartis AG
- NovelMed Therapeutics Inc
- Ophthotech Corp
- Ra Pharmaceuticals Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mtg8gx/geographic?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005430/en/